A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524160-38-00

Enrollment

Registered

2026-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Gastrointestinal Stromal Tumor, Advanced Pheochromocytoma/Paraganglioma, Advanced Solid Tumors With HIF-2α related Genetic Alterations, biliary tract cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, non-MSIH/dMMR endometrial cancer, pancreatic ductal adenocarcinoma, Pancreatic Neuroendocrine Tumor, Renal Cell Carcinoma, von Hippel-Lindau (VHL)Disease-Associated Tumors

Brief summary

Overall survival (OS)

Detailed description

Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Treatment Due to AEs

Interventions

DRUGBelzutifan

DRUGLenvatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Treatment Due to AEs	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 30, 2026